← Back to Search

CAR T-cell Therapy

ET140203 T Cells for Liver Cancer

Phase 1 & 2

Waitlist Available

Research Sponsored by Eureka Therapeutics Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Child-Pugh A6 or better

Molecular Human Leukocyte Antigen ("HLA") class I allele typing confirms participant carries at least one HLA-A2 allele

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 2 years

Awards & highlights

Study Summary

This trial will test a new treatment for liver cancer that uses the patient's own T-cells. Researchers will see how well it works and if it is safe.

Who is the study for?

Adults with advanced liver cancer (Hepatocellular Carcinoma) who have high levels of a protein called AFP, carry the HLA-A2 gene, and whose cancer is not removable by surgery. Participants must have tried at least two other treatments without success, be relatively healthy otherwise, and expected to live at least 4 more months.Check my eligibility

What is being tested?

The trial is testing ET140203 autologous T cell product in adults with liver cancer. It's an early-phase study to see if this treatment is safe. Patients will receive their own modified T cells designed to target their tumor.See study design

What are the potential side effects?

While specific side effects for ET140203 are not listed here, similar therapies can cause immune reactions, flu-like symptoms, fatigue, fever, chills or breathing difficulties. Side effects vary from person to person.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My liver functions well despite my illness.

Select...

I carry the HLA-A2 gene.

Select...

I am mostly able to care for myself but may not be able to do active work.

Select...

My liver cancer is confirmed and my AFP levels are high.

Select...

I have tried at least two treatments for liver cancer that didn't work or caused side effects.

Select...

My liver cancer cannot be removed with surgery and has spread.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Incidence rates of adverse events (AEs) after infusion of ET140203 T cells

Incidence rates of dose limiting toxicities (DLTs) after infusion of ET140203 T cells

Severity rates of adverse events (AEs) after infusion of ET140203 T cells

+1 more

Secondary outcome measures

Assess the efficacy of ET140203 T cells in adults with advanced HCC.

Determine the pharmacokinetics of ET140203 T cells after infusion.

Trial Design

1Treatment groups

Experimental Treatment

Group I: ET140203 TCellsExperimental Treatment1 Intervention

ET140203 T Cells

0 / 6Eligibility criteria met

Find a Location

Who is running the clinical trial?

Eureka Therapeutics Inc.Lead Sponsor

11 Previous Clinical Trials

154 Total Patients Enrolled

5 Trials studying Liver Cancer

59 Patients Enrolled for Liver Cancer

Karen B CravottoStudy DirectorEureka Therapeutics Inc.

Pei Wang, PhDStudy DirectorEureka Therapeutics Inc.

3 Previous Clinical Trials

66 Total Patients Enrolled

1 Trials studying Liver Cancer

15 Patients Enrolled for Liver Cancer

Media Library

ET140203 autologous T cell product (CAR T-cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT04502082 — Phase 1 & 2

Liver Cancer Research Study Groups: ET140203 TCells

Liver Cancer Clinical Trial 2023: ET140203 autologous T cell product Highlights & Side Effects. Trial Name: NCT04502082 — Phase 1 & 2

ET140203 autologous T cell product (CAR T-cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04502082 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this research program open for recruitment?

"Yes, as per the information on clinicaltrials.gov, this trial is currently recruiting participants. The initial posting for this study was made on April 14th 2021 and it has been recently updated on July 1st 2022. There are 50 spots available across five different medical centres."

Answered by AI

What is the current sample size for this experiment?

"Affirmative. Clinicaltrials.gov reveals that this investigation, which was initially published on April 14th 2021, is actively seeking recruits. Approximately 50 participants need to be identified from 5 distinct clinical facilities."

Answered by AI

What is the scope of the clinical trial in terms of medical centers involved?

"Currently, this scientific trial is operating at 5 distinct medical sites, including Duarte, Sacramento and Irvine. Participants are strongly encouraged to enroll in the nearest clinic which should help minimize their overall travel burden."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1)

2021. "Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04502082.